KRAS Pancreatic Cancer Vaccine Shows Safety and Immune Response: What August 2026’s Breakthrough Means
A 2026 clinical trial found an experimental vaccine targeting the KRAS mutation found in 90% of pancreatic cancers was safe and produced measurable immune responses. A 40-year pharmacist explains this breakthrough, the pancreatic cancer warning signs Americans must know, and the lifestyle risk reduction strategies available today.